Skip to main content
S&P 5007,811.54+0.59%DOW51,654.95+0.83%NASDAQ27,366.17+0.64%BTC$82,516.00+0.84%ETH$2,488.45+0.36%GOLD$4,220.30+1.52%OIL$91.66+0.19%
Smart Investors Daily
SID Premium
SP

NASDAQ · SPRC

SciSparc Ltd.

Healthcare · Biotechnology

$4.47

Up+$0.04 (+0.90%)

Updated Oct 12, 2026, 5:56 AM

SID Score

3.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
989.05K
P/E ratio
-0.08
Dividend yield
0.00%
52-week range
$2.98 – $43.65
Volume
4.82K
Avg. volume
5.58M

Price performance · SPRC

SPRC price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 9, 2026

SPRC closed at $4.47 after 20 trading sessions, down 8.96% for the selected period.

Last close
$4.47
Period change
-8.96%
Period low
$4.33
Period high
$5.39
Daily close
View OHLC price history
SPRC OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 9, 2026$4.4719$4.60$4.29$4.474.82K
Oct 8, 2026$4.44$4.499$4.34$4.436K
Oct 7, 2026$4.40$4.70$4.40$4.6440.81K
Oct 6, 2026$4.40$4.4627$4.20$4.336.21K
Oct 5, 2026$4.52$4.60$4.30$4.3614.29K
Oct 2, 2026$4.5665$4.90$4.50$4.722.9K
Oct 1, 2026$4.5473$4.55$4.5473$4.551.47K
Sep 30, 2026$4.61$4.83$4.60$4.7212.19K
Sep 29, 2026$4.91$4.93$4.5957$4.70515.8K
Sep 28, 2026$5.21$5.21$4.91$4.916.57K
Sep 25, 2026$5.2755$5.31$5.21$5.219K
Sep 24, 2026$4.88$5.60$4.88$5.3997.71K
Sep 23, 2026$4.67$5.51$4.3917$5.01106.96K
Sep 22, 2026$4.63$4.70$4.50$4.574.6K
Sep 21, 2026$4.6427$4.6427$4.45$4.534.75K
Sep 18, 2026$4.48$4.64$4.45$4.513.06K
Sep 17, 2026$5.1893$5.1893$4.39$4.4524.21K
Sep 16, 2026$4.88$4.88$4.65$4.689.65K
Sep 15, 2026$5.14$5.14$4.72$4.7612.61K
Sep 14, 2026$4.9601$5.08$4.90$4.914.97K

Latest SPRC news

The latest Smart Investors Daily articles mentioning SPRC.

Stock researchCompany · Overview

SPRC research

Overview

Company profile and research snapshot.

Company profile

SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 7, 2026

SciSparc: Subsidiary NeuroThera Labs’ CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company’s Quantum Architecture

TEL AVIV, Israel, Oct. 07, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, that CliniQuantum Ltd. (“CliniQuantum”), NeuroThera’s majority owned subsidiary, reported that its Graphics Processing Unit- accelerated (“GPU”) quantum-simulation platform achieved an approximately 16.8-

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By